

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 December 2005 (01.12.2005)

PCT

(10) International Publication Number
WO 2005/112900 A1

(51) International Patent Classification⁷: A61K 9/44

Allan, S. [US/US]; 7011 Mallorca Crescent, Boca Raton, FL 33433 (US).

(21) International Application Number:

PCT/US2005/018631

(74) Agent: **COSTIGAN, James, V.**; Hedman & Costigan, P.C., 1185 Avenue of the Americas, New York, NY 10036 (US).

(22) International Filing Date: 23 May 2005 (23.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/573,042 21 May 2004 (21.05.2004) US
60/573,134 21 May 2004 (21.05.2004) US

(71) Applicant (for all designated States except US): **SO-LAPHARM, INC.** [US/US]; 1000 S Pine Island Road, Suite 230, Plantation, FL 33324 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(72) Inventors; and


(75) Inventors/Applicants (for US only): **SOLOMON, Lawrence** [US/US]; 7810 Alton Villa CT., Toronto, Ontario M5R 3B7, Boca Raton, FL 33433 (US). **KAPLAN,**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: PHARMACEUTICAL TABLETS COMPRISING TWO OR MORE UNITARY SEGMENTS

(57) Abstract: Accurate means of dosing with a compressed, segmented pharmaceutical tablet, and tablettes formed from said tablets, is disclosed.



WO 2005/112900 A1



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

5 PHARMACEUTICAL TABLETS COMPRISING TWO OR MORE
 UNITARY SEGMENTS

 FIELD OF THE INVENTION

10

The invention is concerned with a pharmaceutical tablet containing at least three segments, two of which are compositionally identical and are formed from the same layer or layers. The invention addresses imprecise
15 breaking of pharmaceutical tablets.

 BACKGROUND OF THE INVENTION

Pharmaceutical tablets have long been produced with an
20 indentation known as a score, which both locates and tends to physically assist in breaking said tablets into smaller units, called tablettes herein, that are intended to serve as dosage forms. Unfortunately, numerous problems have attended breaking scored tablets, as delineated:

25

Many drugs require dosage adjustments, such as warfarin, the scored tablets of which are frequently broken. These dosage adjustments through tablet breaking by patients have been determined to be imprecise. As the following
30 discussion demonstrates, for many years experts have called upon the pharmaceutical industry to improve the quality of tablet breaking, yet such has not been optimized until the current invention.

In 1984, Stimpel et al. ("Stimpel"), described the relative accuracy of breaking of various tablets for treatment of cardiovascular problems. M. Stimpel et al., "Breaking
5 Tablets in Half." *The Lancet* (1984):1299. Even though breaking was performed by a sophisticated, dexterous person, Stimpel found that breaking was not accurate, and opined that real world use by patients would provide yet more unsatisfactory results. Stimpel called upon the
10 pharmaceutical industry to improve the accuracy of splitting tablets: "Clearly any assumption that halving a tablet will not lead to inaccurate doses is invalid. This potential source of inaccuracy could be even more significant in clinical situations (our study was done
15 under ideal conditions) and the pharmaceutical industry should tackle it, either by improving divisibility (as already has been done for lopressor and logroton) or, even better, by marketing a wider range of unscored tablets to provide all the doses that might be indicated clinically."

20
Despite that finding and statement, and despite the issuance of various patents relating to optimizing a scoring pattern and/or tablet shape, Rodenhuis et al., (2004) noted that: "Improving the functioning of score
25 lines may be a more practical approach than *banning* this dosage form." (emphasis added). N. Rodenhuis et al., "The rationale of scored tablets as dosage form." *European J. of Pharmaceutical Sciences* 21 (2004):305-308 (hereafter "Rodenhuis"). Rodenhuis observed that European regulatory
30 authorities started a policy to discourage scoring of tablets in 1998. This policy change, according to Rodenhuis, likely related to "many recent reports of bad functioning score lines", that "many scored tablets are

difficult to break", and that "many scored tablets show unsatisfactory mass uniformity of the subdivided halves". The authors then go on to describe useful aspects of scoring tablets. For a comprehensive review article on this topic, see van Santen, E., Barends, D.M. and Frijlink, H.W. "Breaking of scored tablets: a review." *European J. of Pharmaceutics and Biopharmaceutics* 53 (2002):139-145.

Some current studies that demonstrate the severity of the problem are described below.

Peek et al., (2002), studied tablet splitting by "elderly patients" aged 50-79. Peek, B.T., Al-Achi, A., Coombs, S.J. "Accuracy of Tablet Splitting by Elderly Patients." *The Journal of the American Medical Association* 288 No.4 (2002):139-145. Breaking scored tablets with mechanical tablet splitters without specific instruction led to highly unsatisfactory separating of the tablets. For example, warfarin 5 mg was on average split into 1.9 and 3.1 mg tablets. This potent anticoagulant has such a narrow therapeutic range that 2, 2.5, and 3 mg tablet doses are manufactured. Biron et al., (1999), demonstrated that warfarin 10 mg also often split to less than 4.25 or greater than 5.75 mg. Biron, C., Liczner, P., Hansel, S., Schved, J.F., "Oral Anticoagulant Drugs: Do Not Cut Tablets in Quarters." *Thromb Haemost* 1201 (1999). In addition, they demonstrated that loss of mass due to crumbling or chipping due to breaking of the warfarin tablets was statistically significant. They also demonstrated that quartering of the tablets was grossly inaccurate.

McDevitt et al., (1998), found that 25 mg unscored hydrochlorothiazide (HCTZ) tablets were manually split badly enough that 12.4% deviated by more than 20% from

ideal weight. McDevitt, J.T., Gurst, A.H., Chen, Y.
"Accuracy of Tablet Splitting." *Pharmacotherapy* 18
No.1(1998):193-197. 77% of the test subjects stated that
they would be willing to pay a premium for individually
5 produced 12.5 mg HCTZ tablets rather than split unscored 25
mg tablets.

Rosenberg et al., (2002), studied pharmacist-dispensed
split tablets. Rosenberg, J.M., Nathan, J.P., Plakogiannis,
10 F. "Weight Variability of Pharmacist-Dispensed Split
Tablets." *Journal of American Pharmaceutical Association* 42
No.2 (2002):200-205. They found that "tablet splitting
resulted in an unacceptably high incidence of weight
variation." They recommended that "standards should be
15 developed to ensure uniformity of split tablets."

Teng et al., (2002), using a trained individual in a
laboratory setting to split tablets, concluded that "the
majority of the 11 drug products we tested, when assessed
20 for their ability to be split into half-tablets of equal
dose, failed a liberally interpreted USP (United States
Pharmacopeia) uniformity test. . . The practice of dividing
tablets to save costs or to improve a dosage regimen . . .
is not recommended for patients using drugs with more
25 substantial toxicity and steep dose-response efficacy
curves." Teng, J., Song, C.K., Williams, R.L., Polli, J.E.
"Lack of Medication Dose Uniformity in Commonly Split
Tablets." *Journal of American Pharmaceutical Association* 42
No. 2 (2002):195-199.

30

Rodenhuis reported that 31% of all tablets in one
Netherlands study were subdivided before being swallowed.
In the U.S., many "managed care" insurance organizations

encourage patients to split tablets which may be unscored and irregularly-shaped. Many drug products in the US are either unscored or are provided as capsules despite being able to be produced as tablets.

5

In the spirit of improving the above problems, the inventors have devised improvements in tablet design and structure as demonstrated below.

10

SUMMARY OF THE INVENTION

The invention provides novel pharmaceutical tablets having compositionally substantially identical first and second
15 "unitary segments" that each adjoin the same face (surface) of a compositionally distinct first non-unitary segment. Said pharmaceutical tablets preferably comprise two or more compositionally identical unitary segments including a first unitary segment and a second unitary segment, said
20 first unitary segment and said second unitary segment containing a drug or drugs, said first and second unitary segment having been formed from the same layer or layers that was or were divided; said first segment optionally having a score on its surface positioned between said first
25 and said second unitary segments; said tablet optionally having additional unitary segments; and said tablet having at least one segment that is not a unitary segment.

The pharmaceutical tablet as defined herein may have one or
30 more additional unitary segments in addition to said first and second unitary segments that are optionally present and that are derived from the same layer or layers as said first and second unitary segments.

The invention involves pharmaceutical tablets that are most conveniently produced as compressed tablets.

A preferred machine with which to produce said tablets is a
5 bi-layer, tri-layer, or five-layer tablet press (or, tableting machine).

As described herein, the preferred method of making the tablet of the invention utilizes a protuberance known as an
10 embossing that rises from the lower punch of a tablet die in a tableting machine. In a preferred method of manufacturing, a granulation preferably containing a therapeutic amount of an active pharmaceutical ingredient enters the die, preferably forms a layer above the highest
15 point of said embossing, and is tamped by the upper punch. Next, a second granulation that is different from said first granulation enters said die on top of said first granulation, preferably is tamped by the upper punch, and then the tablet is compressed by the upper punch so that
20 said compression pushes said first granulation below the highest points of said embossing. In the invention, said embossing occupies a position on the lower punch that may bisect or quadrisection said lower punch, so that said compression causes said first layer to be divided into two
25 or more non-contiguous segments. Said first layer formed from said first granulation is herein referred to as a divided layer; said segments formed from a divided layer are herein referred to as unitary segments. The invention therefore allows precise division of said tablet, when
30 desired, by allowing breaking to occur only through the second layer that was formed by said second granulation so that maximal accuracy of dosing with a tablet fragment arising from intentional tablet breaking may occur. In the

above example, said second granulation preferably lacks an active drug (i.e., it is an inactive granulation).

Less preferred methods than the above of manufacturing
5 tablets of the invention are disclosed subsequently.

When tablets of the invention are broken, the term "tablette" is utilized herein to denote the major fragments arising from said breaking. Breaking a tablet as in Fig. 1
10 through a bisecting score creates two tablettes, each containing very similar quantities of active ingredients if the tablet is broken through a largely inactive segment. Small chips and crumbs that typically are formed when a tablet is broken are not considered tablettes.

15 The invention preferably utilizes the term "segments" in describing the structure of a tablet. The discrete, non-contiguous parts of a divided layer are considered to be segments. Less preferred but possible is a situation in
20 which two substantially identical layers enter the die first and second, are followed by a third, different layer, and then compression pushes both of the first two granulations (which are the first two layers) below the highest point of the embossing arising from the lower
25 punch, forming unitary segments. In this case, it is not one but two layers that are part of the structure of each unitary segment.

30 The invention also utilizes the above-described structure as a core structure that is part of a tablet with segments arising from undivided layers and/or additional unitary segments.

Accordingly, it is a primary object of the invention to provide a novel tablet that is adapted to be broken into two or more substantially predeterminable doses of a drug
5 or drugs by creating tablettes each containing fewer unitary segments than are present in the whole tablet.

It is also an object of the invention to provide a novel tablet that if crumbs or chips are formed by said tablet
10 breaking, the quantity of active drug that is lost is minimized.

It is also an object to provide novel tablets adapted to contain drugs with a narrow therapeutic index or that
15 otherwise have significantly different therapeutic or toxic effects with relatively modest alterations in dosage, such as warfarin sodium and L-thyroxine.

Because of the fine tolerances of less than one (1) mm
20 involved in the process of manufacturing the tablets of the invention, every tablet may not include unitary segments. However, it is also within the scope of the invention to produce tablets lacking unitary segments, but having a score which penetrates so deeply within a first segment
25 containing a drug towards a second segment that a pharmaceutical tablet with a first segment containing a drug or drugs in which a score that penetrates 95-99% or more of the distance between the origin of said score and the interface between said first and second segments is a
30 part of the present invention. Stated another way, if less than 5% of the mass of a first segment lies between the length of a score that traverses said first segment and the interface between said first and a second segment, then

said tablet is also within the scope of the present invention.

These and other objects of the invention will become
5 apparent from the present specification.

BRIEF DESCRIPTION OF THE FIGURES

10 Fig. 1 depicts a cross-section of a three-segment tablet with one score;
Figs. 2a-b depict cross-sections of the tablettes made by breaking the tablet of Fig. 1;
Fig. 3 depicts a cross-section of a three-segment tablet
15 where the score is made with a triangularly shaped profile;
Fig. 4 depicts a bottom perspective view of a three segment tablet.
Fig. 4b is a cross-section of Fig. 4 taken along lines 4-4;
Fig. 5 is a cross-section of a four segment tablet with a
20 score;
Figs. 6a-b depict two tablettes made by breaking the tablet of Fig. 5;
Figs. 7a-b depict two tablettes made by breaking one of the tablettes of Fig. 6b.

25

DETAILED DESCRIPTION OF THE INVENTION

Before describing the present invention in detail, it is to be understood that this invention is directed to
30 pharmaceutical tablets, preferably those pharmaceutical tablets which are made by compression such as by compression applied in a die in an automated tableting machine, and preferably those pharmaceutical tablets that

are uncoated. Tablets of the invention are not formed using a cement, glue, adhesive, or the like.

If desired, conventional film coatings may be applied to enhance the appearance of the tablets and to facilitate the
5 handling of the tablets. It is also to be understood that in describing and claiming the present invention, the following definitions have been utilized:

A segment represents the entirety of a contiguous,
10 substantially homogeneous part of a tablet or tablette (see below) of the invention.

A compressed layer that is not adjacent to a layer formed from a substantially identical granulation that formed said
15 first-mentioned layer is a "simple segment." Tablets of the invention comprise two or more segments, and each segment may be formed from two or more layers.

The term "unitary segment" means a physically separated,
20 non-contiguous part of a divided layer or layers of a tablet and which may be made using a bottom embossed die that causes granulate to be divided as it enters the tablet die or after compression by an upper punch in the die; or, by a post-tabletting scoring that removes a part of a
25 segment to a depth that exposes an underlying segment.

A layer is produced by introducing an amount of an individual granulation into a tablet die to fill at least a part of the die. A layer is considered to exist whether it
30 is in the form of an un-tamped, tamped or fully compressed granulation. Because some migration of granulation may take place in the tabletting machine, some amount (preferably of no therapeutic importance) of a granulation that forms one

layer may be transferred to another layer.

The terms "active agent," "drug," "active drug," active
5 pharmaceutical agent," "pharmacologically active agent" are
interchangeable and include, without limitation,
prescription and non-prescription pharmaceutical compounds,
as well as pharmacologically effective doses of vitamins,
cofactors, and the like. Not considered a "drug" herein
10 are such substances as foodstuffs or vitamins in
"recommended daily allowance" quantities.

The term "interface" refers to that part of the tablet
representing the region at which two layers adjoin one
15 another.

The term "undetectable amount" means that using
conventional analytical techniques such as high performance
liquid chromatography (HPLC), nuclear magnetic resonance
20 (NMR) and the like, the presence of an active compound can
not be detected. The term "pharmacologically ineffective
amount" means an amount that has no pharmacological effect.
It is understood that due to the conditions under which
high speed automated tableting equipment are operated,
25 some unintentional mixing of different granulations may
occur which may cause amounts, preferably trace, of one
granulation to appear in a segment where it was not
intended to be placed.

30

The terms "horizontal," "transverse," and "vertical" when
used in relation to a tablet, are based on the spatial
orientation of the tablet as, and after, it is produced in

a die, but before removal or ejection from the die. The first granulation into a tablet die produces the bottom layer. In the tablets of the invention, most often said first layer becomes a divided layer after tamping or final
5 compression, a divided layer from which a plurality of unitary segments are created. Said first granulation, divided layer, and unitary segments occupy the bottom of said tablet. If said tablet is composed of said unitary segments and a second, undivided layer that forms another
10 segment that is not a unitary segment, then said non-unitary segment represents the top of said tablet. The parts of the tablet that are in contact with the internal, usually vertically-oriented faces of said tablet die are the sides of said tablet.

15

A tablet of the invention containing a bottom divided layer and a top undivided layer, and no other layers, is usually wider than it is tall. The width is the greatest transverse dimension representing the perimeter of the
20 transverse cross-section tablet, such as the longer side of a rectangular (non-square) perimeter. When the invention is created with a bottom embossing that separates the bottom layer to become a divided layer, preferably said embossing also penetrates into the immediately superior
25 segment to cause said superior segment to have a score.

The following describes a method of manufacture of a preferred embodiment of the invention:

A granulation enters the die of a tablet press, such as a
30 standard bilayer high-speed press. The granulation is optionally tamped and forms a layer that is indented from below by an embossing present on the bottom punch. Said embossing may be in the form of a bisecting embossing or

may be more complex and may involve more than one score. At a second filling station, a second, non-identical granulation that is preferably comprised of inactive excipients enters the die and is optionally tamped. At the
5 same filling station, a full compressive force is applied, sufficient to push both layers downward, so that the first, bottom layer is pushed substantially completely to the level of the upper part of the embossing of the bottom punch. If said uppermost aspect of said embossing reaches
10 up to or, preferably, into said second layer, then a novel tablet has been created. This tablet comprises as its first layer what is called herein a divided layer. The discrete parts of a divided layer are without contiguity and are called unitary segments herein.

15

A layer is thus formed when a granulation has completely entered a tablet die. A layer is considered to be present after said granulation has fully entered said die, after any tamping has occurred, and after final compression to
20 form a compressed tablet. Tablets of the current invention require two compositionally non-identical ("different") granulations and therefore are formed from a plurality of layers.

25 Functional units of the compressed tablets of the invention are generally referred to as segments, not layers, because of the following considerations. If two identical granulations were poured sequentially into the die at two consecutive filling stations, then the compressed tablet
30 containing both layers formed from said granulations would not be in practical terms distinguishable from each other; they would function as one segment (a "compound segment" herein, as such a segment is formed from a plurality of

contiguous layers). A segment formed from one layer is a simple segment. The novel segments of the invention generally derive from one layer. The divided layer gives rise to two or more "unitary segments." In the less preferred case that two consecutive substantially identical granulations enter the die consecutively and both become divided and then a compressed tablet is formed, then unitary segments that are also compound segments will have been formed.

10

In addition, the invention requires a layer to be divided. Each non-contiguous part of the tablet formed from the parts of a layer may be considered a segment. In general, tablets of the invention are formed from one divided layer that gives rise to two or more segments. Segments formed from a divided layer are called "unitary segments" herein. In certain cases, however, two compositionally substantially identical granulations may enter the die and both give rise to divided layers. The contiguous parts of the divided layers would then comprise unitary segments that have the feature described above of being "compound."

20

In most cases, the basic invention will tend to have one "supporting" or "backing" layer that is also denoted as a segment. A segment formed from one layer not contiguous with a compositionally substantially identical layer is a simple segment. In most cases, a unitary segment is formed from one layer and is therefore also a simple segment.

25

Current methods of manufacture produce tablets with one granulation entering the die on top of another, so that tablets of the invention produced in such a manner comprise one or more top (outer) segments, one or more bottom

(outer) segments, and optionally one or more inner segments. A segment that is not a top or bottom (i.e., outer) segment is considered to be an inner segment. Inner segments have sides that are external and that may play an important role, as they may come to be scored, broken through, etc., if the tablet contains unitary segments adjoining a first segment not formed from a divided layer, and said first segment on its face opposite that adjoining said unitary segment adjoins another segment. Neither the number of inner segments, nor the number of unitary segments that adjoin an inner segment, is limited to one.

Certain important embodiments of the invention involve one or more additional segments added vertically on top of the segment that adjoins a bottom divided layer (i.e., a plurality of unitary segments). In one case, a compositionally substantially identical granulation to that forming said bottom divided layer may comprise the upper segment of the tablet. Thus, the tablet may comprise three layers and four segments: two bottom unitary segments formed from one layer; an inner segment formed from an inactive granulation that has adequate height to be broken substantially through said segment only; and, a top segment containing substantially the same granulation in the same quantity that formed the bottom divided layer. Thus, a tablet would thereby allow breaking through the inner segment into two parts ("tablettes") each of which contain the same quantity of drug (i.e., half the dose present in the whole tablet). Then, the tablet containing the unitary segments could further be divided to give two quarter doses.

In another preferred embodiment that is a variation of that

described immediately above, an upper segment may comprise a different drug than does a bottom unitary segment. With regard to the unitary segments, the advantage over current practice remains.

5

Tablets of the invention are not limited in dimensions or number of segments. Two or more unitary segments may be formed from a divided layer. A practical limit to the number of unitary segments formed from one layer in a tablet suitable as a whole tablet for human oral ingestion is eight. In addition, while less preferred, a tablet may have two different types of unitary segments, caused by the formation of two divided layers each formed from different granulations.

15

In addition, an undivided segment that adjoins unitary segments may be formed from a granulation that contains a different drug than that present in the granulation forming the unitary segments, or may contain the same drug as in said granulation but in a different, and most preferably diminished, concentration.

20

While not depicted in a diagram, a tablet may be formed from an inner undivided layer which has unitary segments on opposite faces.

25

In addition, it is technically feasible to produce unitary segments from a layer that leaves the die as an undivided layer, such as by taking a file or abrasive or cutting instrument and removing sufficient material from one segment to cause it to become a plurality of non-contiguous segments. Such a technique could allow an upper segment of the tablet described in the paragraph immediately above to

30

be created. In addition, such a technique could also allow a two-layer tablet to exist in which each layer gives rise to a unitary segment. This could be done, for example, by taking the tablet of Figure 1 and creating a notch, in a
5 location other than directly over the score in the lower aspect of said upper segment, in a manner such as via a file, which extends into one of the unitary segments. Such an embodiment is a less preferred embodiment.

10 The novel dosage forms may contain a divided layer (or layers) and a plurality of unitary segments arising from said divided layer (or layers). Tablets of the invention with the structure as depicted in Fig. 1, Fig. 3, and Fig. 4 are intended to be broken, if it is desired to create
15 accurate smaller doses of active drug than are present in the whole tablet, through the undivided, upper segment, such as by locating the space between two or more unitary segments and applying force to the undivided segment so that substantially all tablet breaking takes place in said
20 undivided segment, that preferably contains a minimal amount of drug, or in some cases, contains a drug for which accurate breaking is of diminished importance. Examples of such drugs could include folic acid or "B complex" vitamins in pharmacologically effective doses, or potentially a drug
25 that treats hypertension that has a wide dosage range over which the pharmacologic effect changes little. Alternatively, a tablet as in Figs. 1, 3, and 4a-b, may be broken by grasping the tablet at its ends and applying force so that, as the potentially weakest region, breaking
30 occurs centrally through the region of the non-unitary segments by the space between said unitary segments and gives the intended break.

The tablets of the invention may be broken in standard ways, according to the invention such as either by applying force such as a cutting edge directly to the desired breaking region as described above or by gripping the ends
5 of the tablet and applying force so that the tablet breaks substantially completely through the undivided segment.

Figures 1-7 depict cross-sectional views of tablets and tablettes of the invention, except for Fig. 4a, which is an
10 external view. The drawings depict vertical cross-sectional views of tablets and tablettes of the invention. Tablets are depicted as if they were in the die, so that the top of the tablet as it is oriented on the page corresponds with the top of the tablet in the die. In
15 other words, the top segment of the tablet as viewed contains the last granulation to enter the die. Tablettes are depicted as they would have been in the die before they were separated from the intact tablet.

The drawings depict vertical cross-sectional views of
20 tablets and tablettes of the invention. Tablets are depicted as if they were in the die, so that the top of the tablet as it is oriented on the page corresponds with the top of the tablet in the die. In other words, the top segment of the tablet as viewed contains the last
25 granulation to enter the die. Tablettes are depicted as they would have been in the die before they were separated from the intact tablet.

"Front views" refer to a cross-sectional view of a tablet
30 that has a theoretical geometric plane passed through the tablet relative to a side which is arbitrarily designated as the front. Figures labeled as "side view," which also have a corresponding "front view" are taken as a cross-section through the whole tablet from the right side of a

front view i.e., a side view is a cross-section that is taken by passing a plane through the vertical axis of the whole tablet at a 90° angle to the cross-sectional front view. Each front view represents a schematic cross-section
5 that passes through the midpoint of the horizontal cross-section as measured from the front of the tablet to the back of the tablet or tablette. The front view is also parallel to the major axis of the tablet (e.g., for a tablet with a rectangular (but not square) transverse
10 cross-section, the longer side of the perimeter is parallel with the plane that depicts the cross-sectional, front view.

That plane is located half-way between the front and back surfaces of said tablet.

15

Cross-sections of segments are shown crosshatched if they contain a drug and if they lack a pharmacologically effective quantity of drug, they are shown plain (clear, without crosshatching or stippling). The upper part of
20 each figure corresponds to the upper part of a tablet, all of which are depicted as they are situated within a die after final compression and before ejection from the die. For consistency, tablettes are depicted in the same orientation as the tablets from which they are formed,
25 although tablettes are created after tablet ejection from a die.

Tablettes are depicted with broken surfaces as indicated by a fine saw-tooth pattern. Such saw-tooth depiction is
30 schematic and not intended to represent the actual pattern of breaking of a tablet or tablette.

Tablets of the invention have the core structure A'A''/X

where A'A'' represents the substantially identical unitary segments formed from a (completely) divided layer most preferably containing a drug; X represents a segment generally representing an undivided layer and one face
5 (surface) of X adjoins both A' and A''; X is preferably scored on the surface to which A' and A'' adjoin, to aid tablet breaking. (X may optionally be scored on another surface, as well.) The number of unitary segments formed from a layer is not limited to two; a bottom embossing
10 pattern involving three parallel scores or two crossing scores may allow four compositionally substantially identical unitary segments to be produced.

Tablets of the invention may be manufactured by the above.
15 technique and related techniques. For example, a minimal amount of granulation may enter the die and rest on an embossed lower punch. If the embossing is high enough and the quantity of granulation is small enough, the layer formed from the granulation may be a divided layer even
20 before any further compression occurs; this situation is less preferred, however, as there may not be the generally desired equality of mass between said unitary segments. In another example, a first and second feed of substantially identical granulations may enter the die onto an embossed
25 lower punch with one bisecting score, followed by a third, non-identical feed. If final compression pushes said first and said second granulation below the uppermost part of said embossing, then the first two granulations will have formed two divided layers of a three-layer tablet, but
30 collectively the two divided layers will have formed two and not four unitary segments; each segment will consist of approximately half of each divided layer.

In another example, a layer may not comprise a divided layer until a tablet has been formed and ejected from the die. In such a case, application of force, such as by a knife or a cutting instrument, may be utilized to remove
5 sufficient material containing drug so that a score is cut into the undivided segment. This technique could be useful in cases in which an upper punch contains an embossing and a deep score is created in the upper segment, but a small amount of said segment remains, and could be removed
10 subsequent to tablet ejection from the die.

Fig. 1 depicts a tablet containing unitary segments 272 and 274 in vertical cross-section, front view. Both of said unitary segments adjoin the same face (surface) of segment
15 270, which is formed from a single granulation and due to mixing of granulations, contains a minimal amount of the drug that is present in segments 272 and 274. Interfaces 276 and 278 represent the regions at which segment 270 adjoins segments 272 and 274, respectively. Score 280
20 indents segment 270 and also represents the space between segments 272 and 274.

Figs. 2a and 2b depict the two tablettes created by breaking the tablet of Fig. 1 through segment 270. In Fig.
25 2a, segment 302 represents that part of segment 270 that adjoins intact segment 274. Interface 278 represents the region at which segments 302 and 274 meet. In Fig. 2b, interface 276 represents the region at which segments 304 and 272 meet. Score 280 and segment 270 of Fig. 1 are not
30 considered to exist once the tablettes are formed. Each tablette of Figs. 2a and 2b contains substantially equivalent mass assuming the score 280 of Fig. 1 is a bisecting score relative to the layer that became divided

in the creation of segments 272 and 274.

Tablets of the nature of that of Fig. 1 may contain in the unitary segments a mixture of drugs or, as in Fig. 1, one
5 drug. In addition, the granulation that forms segment 270 of Fig. 1 may be provided with a drug that is the same as, or different than, that of the divided layer. In this case, it would be likely that said drug provided in the upper layer would have a therapeutic effect and side effect
10 profile that was not very sensitive to accuracy of subdivision of a dose.

In addition, no limitation exists as to the presence of one or more additional segments created superior to (i.e.,
15 above) 270, or the composition of such. Also, though less likely, there could be another set of different unitary segments inferior to (i.e., below) segments 272 and 274.

Fig. 3 depicts a tablet similar to that depicted in Fig. 1,
20 but the tablet of Fig. 3 has a score 300 that extends more deeply into the non-unitary segment 290 than does score 280 of Fig. 1. One way of producing score 300 is to use the embossing and manufacturing technique used for the tablet of Fig. 1 and then remove, such as with a file, material
25 from segment 290. Alternatively, embossing of the appropriate size and shape may be able to be utilized to create score 300 directly. The tablet of Fig. 3 contains unitary segments 292 and 294. Interfaces 296 and 298 are present between segments 292 and 290, and 294 and 290,
30 respectively.

Fig. 4a depicts an external view of a tablet containing unitary segments 604 and 606 that are at the bottom of the

tablet. In this tablet, score 610 penetrates into clear, upper, non-unitary segment 608. Interface 602 represents the region at which segment 608 meets segment 604. Interface 612 represents the region at which segment 606
5 meets segment 608.

Fig. 4b depicts the same tablet depicted in Fig. 4a. This vertical cross-section is taken perpendicularly through score 610, which occupies the diameter of the circular
10 transverse cross-section of the tablet.

Fig. 5 depicts a tablet containing four segments. Unitary segments 6 and 8, as with all unitary segments, are not contiguous with each other. Score 10 penetrates into
15 segment 4. Segment 4 is a compound segment formed from substantially compositionally identical inactive granulations added sequentially. Top segment 2 contains a therapeutic quantity of a drug that differs from the drug that is present in a therapeutic quantity in segments 6 and
20 8. Dotted line 12 reflects a surface score that runs transversely across segment 4. A preferred horizontal dimension for the tablet of Fig. 5 is 12-18 mm, but said dimension is not limited. Interface 14 depicts where segments 2 and 4 are contiguous. Interfaces 15 and 16
25 depict where segments 6 and 8, respectively, adjoin segment 4. Segment 4 contains therapeutically insignificant quantities of the drugs found in segments 6 and 2.

The tablet of Fig. 5 may be broken usefully in two ways. One way is vertically through score 10 in the direction of
30 segment 2; such breaking would not utilize the score reflected by dotted line 12, but would give a dose of half of the drug found in segments 6 and 8, though likely would not give a precise halving of the drug found in segment 2,

due to difficulties with breaking scored tablets as was documented in the Background of the Invention, above. The result of another way of breaking said tablet is depicted in Figs. 6a and 6b.

5 Fig 6a shows a tablette formed from breaking the tablet of Fig. 5 through the horizontal score reflected by dotted line 12. As with other tablettes depicted herein, it is not assumed that breaking is even, but the tablettes are depicted so that breaking is contained substantially within
10 segment 12, that is a segment interposed between upper segment 2 and lower segments 6 and 8 in the tablet of Fig. 5. The tablette of Fig. 6a demonstrates that segment 2 is intact, as is interface 14. Segment 3 is formed by the part of therapeutically inactive segment 4 of the tablet of
15 Fig. 5 that remains contiguous with segment 2. The tablette of Fig. 6b depicts segments 6 and 8, and interfaces 15 and 16, as unchanged from the tablet of Fig. 5. Segment 7 is the part of segment 4 of Fig. 5 that becomes part of the tablette of Fig. 6b.

20

Figs. 7a and 7b depicts the result of a second breaking, that of the tablette of Fig. 6b. Fig. 7a depicts segment 8 that now adjoins new segment 11, formed from segment 7 of the tablette of Fig. 6b. Interface 16 and segment 8 are
25 unchanged from that of the whole tablet of Fig. 5. Fig. 7b depicts segment 9, formed from segment 7 of Fig. 6b, and segment 6 and interface 15, which are unchanged from the whole tablet of Fig. 5.

30 Thus, Figs. 7a and 7b, in association with Figs. 5, 6a, and 6b, demonstrate a means by which a combination tablet can be divided not only to separate therapeutic quantities of one active drug from another, but also then precisely give

a partial dose of one of said active drugs.

The invention also includes the method of administering one
5 or more drugs via the dosage forms such as tablets and
tablettes of the invention to a patient, mammal, or other
animal in need of pharmaceuticals for the prevention or
treatment of an illness, maintenance of good health,
retarding of aging, or other purpose. Included are methods
10 of treating a patient with only one drug from a combination
product, such as with a novel tablette of the invention,
enabling downward dose adjustment for a variety of reasons;
or, in a similar vein, a patient may be treated with one
whole tablet containing a plurality of active drugs and in
15 addition receive only one drug from a similar tablet, thus
enabling upward dose adjustment. Combination products that
can benefit from the invention, in which one drug is in an
outer active segment, and a second and different drug is in
the other outer active segment, and an inactive middle
20 segment as in embodiments such as was described in
paragraphs 3 and 4 above, include those containing the
following pairs of drugs: amlodipine and either benazepril,
chlorthalidone, or atorvastatin; benazepril and
hydrochlorothiazide; olmesartan and hydrochlorothiazide;
25 and many others, including the majority of the currently-
produced combination products. Also included is the method
of treating a patient with a precise partial dose of
medication from a whole tablet, which may be a half or
quarter of the whole dose, but may usefully be a different
30 fraction. Warfarin especially may usefully be produced and
dosed according to the invention with separable segments of
the tablet that may but need not be as halves, quarters,
etc. L-thyroxine and digoxin are other examples that could

so benefit, along with warfarin.

The following give possible clinical situations in which the tablets of the invention could provide important
5 benefits.

1. A currently marketed product in the United States is Caduet®, which contains the active ingredients atorvastatin calcium (atorvastatin) and amlodipine besylate (amlodipine)
10 which are largely homogeneously inter-dispersed in an unscored tablet. The product is indicated to treat both hyperlipidemia (atorvastatin) and hypertension (amlodipine). A patient ingesting this tablet daily may then undergo a blood test and be diagnosed as having liver
15 dysfunction as manifested by elevation of an enzyme's concentration in the blood. The physician may then recommend cessation, possibly temporary, of atorvastatin, which is stated by the manufacturer to be a possible cause of liver dysfunction. A patient receiving Caduet, however,
20 would have to thus also discontinue amlodipine, which is not in this example desired by the physician. A tablet of the invention in which atorvastatin and amlodipine were segregated in different outer active segments, separated by a middle segment of adequate dimensions, would be a clear
25 advance over the current Caduet formulation, because such a tablet would allow a patient to promptly continue ingesting amlodipine while stopping ingestion of atorvastatin, without having to go to a pharmacy and fill a new prescription for a tablet containing only amlodipine as the
30 active ingredient, while having previously had the convenience of having both drugs combined in a single dosage form. The above embodiment of the invention represents an improvement over the current Caduet dosage

form.

Another clinical situation in which the invention is superior to Caduet is one in which a patient receiving
5 amlodipine 5 mg once daily and atorvastatin 20 mg once daily is advised by a physician to increase the daily amlodipine dose to 10 mg once daily. A patient in possession of adequate tablets of the invention, with the active drugs segregated in a three-segment tablet, would be
10 able to promptly increase the amlodipine dose by taking a whole tablet of the invention once daily, plus a tablette containing 5 mg of amlodipine, produced by breaking a second whole tablet of the invention.

15 Another clinical situation in which the invention is superior to Caduet involves the case in which a physician wishes a patient to ingest atorvastatin 20 mg each morning and amlodipine 2.5 mg twice daily. The invention provides for amlodipine to be separated from atorvastatin and then
20 broken precisely in half. The invention thus allows the patient the advantage of one tablet, whereas to accomplish this currently in the United States would require one 20 mg Lipitor® (atorvastatin) tablet and two Norvasc® (amlodipine) 2.5 mg tablets.

25

2. The combination of amlodipine besylate and benazepril hydrochloride (benazepril) is marketed in the United States under the brand name of Lotrel®. This product is a capsule that is routinely ingested whole. An embodiment of the
30 invention provides a whole tablet containing one outer segment containing amlodipine as the only active drug and the other outer segment containing benazepril as the only active drug. If desired, either outer layer may be formed

into more than one segment, as in Fig. 1a. As in example 1 above regarding Caduet, the middle segment is inactive and may be broken through to create two tablettes, each comprising a whole amount of each outer active segment plus approximately half of the amount of the middle inactive segment. If a patient were to develop a need for double the dose of one active drug but not the other, the tablet of the invention could meet that need. Alternatively, if a patient were to develop a need to ingest only one active drug, possibly temporarily, due to such conditions as blood pressure changes or a side effect to one drug but not the other, the tablet of the invention allows this to be done without a new dosage form being prescribed.

3. Another use of the invention involves the combination of amlodipine and chlorthalidone or another diuretic, which may usefully be combined to treat hypertension. Benefits of the invention are similar to those described in the paragraph immediately preceding this paragraph.

4. Another use of the invention involves the combination of olmesartan medoxomil (olmesartan, an angiotensin receptor blocker) and hydrochlorothiazide (HCTZ). This product is currently marketed in the United States under the name Benicar/HCT[®], with the doses, respectively, of, in mg: 20/12.5, 40/12.5, and 40/25. A very common starting dose of a patient will be 20/12.5 once daily. The product is currently marketed in all strengths as a homogeneous tablet containing both active drugs. Formulated according to the current invention, a patient who begins treatment with the 20/12.5 dose may be increased with the same tablet to each of the other doses by ingesting one whole 20/12.5 tablet and either a half tablet containing 20 mg of

olmesartan or a half tablet containing 25 mg of HCTZ. This will provide the physician an opportunity to investigate the new dose before giving the patient a new prescription. Other advantages of the invention are similar to those
5 described above.

5. Another useful combination product that may be formulated according to the invention involves angiotensin converting enzyme inhibitors (ACEs) and diuretics such as
10 HCTZ. Both types of drug not uncommonly have side effects, so that the invention will be useful to physicians in dealing with the side effects, as well as with changing dosing needs to deal with the anti-hypertensive and other clinical benefits of the drugs.

15

6. Another product that may benefit from the invention regarding separating active drugs in separate outer layers with an inactive middle segment (layer) is a combination product containing two active drugs, fluoxetine and
20 olanzapine.

No limitation to the above therapeutic fields or to the specific examples within their fields is intended for tablets of the invention, which may be used in any suitable
25 combination of drugs. No limitation to two-drug combinations exists, as well. For instance, one outer active segment of a tablet according to the invention could contain levodopa and carbidopa, and the other outer active segment could contain entacapone, a tablet product
30 containing all three drugs in a homogeneous fashion that is currently marketed in the United States as Stalevo®. Also, a tablet per the invention could involve five layered segments, with, for example, amlodipine in one outer

segment, an inactive segment adjoining it, a middle segment containing chlorthalidone or HCTZ, and a second inactive Segment adjoining both it and the other outer segment that contains benazepril (see Fig. 8). If both inactive
5 segments were of adequate dimensions to be conveniently breakable without damaging any of the three active segments, thus providing significant clinical advantages due to the adoption of flexible dosing of the different active segments.

10

The following list of possible combinations of a plurality of drugs is exemplary and not limiting. The combinations referred to may include two or more members of the classes listed. Drugs listed below, and herein, may for
15 convenience exclude mention of any salt of a drug; e.g., "atorvastatin" is listed even though its marketed form is atorvastatin calcium.

Without limitation, useful combinations may include a
20 plurality of drugs from within the following six drug classes.

In addition, tablets of the invention may be created containing only one of a drug from the following list.
25 With regards to combination use, two methods of use may apply to the invention. One of these methods is to place an individual drug in a granulation and a different individual drug (or combination of drugs) in a different granulation, potentially with an inactive granulation
30 interposed between them; another method is to place a plurality of drugs in one or more segments.

1. Anti-anginal agents, for example:
 - A. Calcium antagonists (see list below);
 - B. Beta-blocker (see list below);
 - C. Organic nitrate preparation (e.g., isosorbide mononitrate or dinitrate).
2. Anti-anginal agent plus an anti-platelet agent, such as aspirin, clopidogrel, or ticlopidine.
3. Two hypoglycemic agents (see list below).
4. Potassium chloride and any thiazide-type or loop diuretic (see lists below).
5. Lipid-lowering agent plus: hypoglycemic agent, anti-platelet agent, anti-anginal agent, and/or antihypertensive agent (see lists above and below)
- 15 Hypoglycemic agents include: thiazolidinediones: pioglitazone, rosiglitazone; sulfonylureas: glyburide, glipizide, glimepiride, chlorpropamide; Biguanides: metformin; Meglitinides: nateglinide, repaglinide;
- 20 Glucosidase inhibitors: acarbose, miglitol.
6. Antihypertensive agents:
 - Beta-blockers: acebutolol, atenolol, bisoprolol, celiprolol, metoprolol, mebivolol, carvedilol (a mixed alpha-beta blocker), nadolol, oxprenolol, penbutolol, pindolol, propranolol, timolol, betaxolol, carteolol;
 - Calcium antagonists (calcium-channel blockers): nifedipine, amlodipine, verapamil, diltiazem, nisoldipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, manidipine;
 - Thiazide-type diuretics (with or without potassium-retaining diuretics such as triamterene, amiloride, or spironolactone): hydrochlorothiazide, chlorothiazide,

cyclopenthiiazide, polythiazide, bendrofluazide,
hydroflumethiazide, chlorthalidone, indapamide,
methylelothiazide, metolazone;
Angiotensin converting enzyme inhibitors: captopril,
5 enalapril, lisinopril, ramipril, trandolapril, quinapril,
perindopril, moexipril, benazepril, fosinopril;
Angiotensin receptor blockers: losartan, valsartan,
candesartan, telmisartan, eprosartan, irbesartan;
High-ceiling (loop) diuretics (with or without potassium-
10 retaining diuretics such as triamterene, amiloride, or
spironolactone): furosemide, torsemide, ethacrynic acid,
bumetamide;
Aldosterone antagonist diuretics: spironolactone,
eplerenone;
15 Alpha-blockers: doxazosin, terazosin, prazosin, indoramin,
labetolol (a mixed alpha-beta blocker);
Central alpha-agonists: clonidine, methyldopa;
Imidazoline: moxonidine;
Direct vasodilators: hydralazine, minoxidil;
20 Adrenergic neuronal blocker: guanethidine.

Lipid-lowering agents include:

Statins: lovastatin, simvastatin, pravastatin,
rosuvastatin, atorvastatin, fluvastatin;
25 Fibrates: clofibrate, bezafibrate, fenofibrate,
gemfibrozil, ciprofibrate;
Others: ezetimide, niacin, acipimox.

The combinations of drugs disclosed herein are for
30 illustrative purposes and are not intended to limit the
scope of the invention.

Regarding the important usage of the tablets and tablettes

of the invention, that involving division of a tablet into
tablets containing similar active segments, most drugs
that may undergo dosage adjustment will be preferred if
they may be divided in an optimally precise manner.
5 Examples of drugs that will especially benefit from the
advances of the invention in this manner include narrow
therapeutic index drugs such as warfarin, digoxin, L-
thyroxine; vasoactive drugs such as amlodipine;
hypoglycemic agents such as rosiglitazone and glipizide;
10 and anxiolytics drugs such as alprazolam. These are
however but a small fraction of the great mass of drugs
that will benefit from the various embodiments and
procedures of the invention.

15 There are numerous methods of use of the dosage forms of
the invention, including its tablets and tablets.
Persons skilled in the medical and pharmaceutical arts will
recognize the many advantages that the various embodiments
of the invention allow over current products. Some
20 examples of benefits of the inventions involving tablets
containing exactly one similar active segment are described
immediately below.

1. Warfarin is an anticoagulant marketed in the U.S. under
25 the brand name Coumadin®, which is a scored tablet.
Research has shown that patients do not break warfarin 5 mg
tablets into equal 2.5 mg segments. The invention teaches
different types of tablets that allow warfarin tablets of
any common human dose to be broken into precise halves, and
30 potentially precise thirds, quarters, etc. (tablets).
Thus a patient may utilize warfarin half-tablets
(tablets) produced as per the invention with similar
confidence as in the whole tablet. Because warfarin doses

are frequently broken, many clinical scenarios exist in which the invention will benefit patients.

2. Norvasc (amlodipine besylate or amlodipine herein) is marketed as unscored 2.5, 5, and 10 mg tablets in the U.S. These tablets are of irregular shape and are difficult to break. The FDA-approved dosage range is from 2.5 to 10 mg ingested orally daily. The invention allows improved functionality of amlodipine. For example, under the invention, a patient receiving 5 mg daily who a physician wishes to increase to 7.5 mg daily may simply utilize a tablet of the invention that comprises two separate 2.5 mg segments to increase the dose to precisely 7.5 mg, such as by ingesting one whole 5 mg tablet and one 2.5 mg tablette created by breaking a 5 mg tablet into two tablettes each containing 2.5 mg of amlodipine. Convenience and cost savings are clear. Similarly, a patient receiving a 10 mg dose of Norvasc who is advised to reduce the dose to 5 mg daily must currently purchase a new prescription for 5 mg Norvasc tablets. The invention provides the ability to provide a 10 mg tablet that may be broken into two tablettes, each containing precisely 5 mg of amlodipine. The invention may therefore enable greater flexibility of treating patients, and provide cost savings as well. A further benefit of the invention is that various embodiments allow fully accurate separation of a tablet into a tablette comprising one-fourth of the dose of the active ingredient as is found in the whole tablet. This may for example be done for amlodipine by providing four active segments all containing 2.5 mg of amlodipine. Thus, a 10 mg amlodipine tablet of the invention may be utilized to provide a 7.5 mg dose; or, it may be utilized to provide four 2.5 mg doses.

A further benefit of the invention may relate to pediatric or geriatric doses, which may not be produced in appropriate dose strengths. In the case of amlodipine, a
5 1.25 mg daily dose may be useful in either small children with hypertension, or in frail elderly patients with angina or hypertension, who may have hepatic dysfunction. Even though the United States Food and Drug Administration (FDA) has not approved a 1.25 mg dose, precise divisibility of
10 the approved 2.5 mg dose would allow a 1.25 mg daily dose. In addition, precise divisibility of the approved 2.5 mg dose will allow accurate dosing of 3.75 mg.

Another use of the invention is to enable a method of cost
15 savings for insurers and patients. The invention allows this because many drugs, such as Norvasc and Coumadin, have pricing that differs little (if at all) between different doses. Because tablet splitting is imprecise for most scored tablets, the practice of mandatory splitting has
20 been met with disapproval by most physician and pharmacist organizations. The invention enables tablet splitting because it provides accurate dosing when a tablet (or some tablets, as in Fig. 1b) of the invention are broken as described herein. Substantial benefits are foreseen from
25 this innovation. In addition, the ability to separate one active drug from another in a combination product has cost saving advantages, as well.

It is recognized that related inventions may be within the
30 spirit of the disclosures herein. Also no omission in the current application is intended to limit the inventors to the current claims or disclosures. While certain preferred and alternative embodiments of the invention have been set

forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art.

5 DESCRIPTION OF THE PREFERRED EMBODIMENTS

A tablet having two unitary segments containing equal amounts of amlodipine adjoining a first upper segment having no drug is made as follows:

10

A Stokes 27-station tri-layer rotary tablet press is used. All formulations are directly compressible powder blends. The blending of the amlodipine formulation is performed in a Patterson-Kelly "V" blender. The first
15 segment consists of Nu-Tab® and requires no blending. The tablets are compressed using tablet punches to a hardness of 35 kilopounds. The amlodipine formulation is introduced first into a die having a wedge shaped embossed bottom section die sized to provide a total of 5mg of amlodipine
20 besylate in each dose. A top die having a flat profile is used to compress the tablet forming ingredients.

	Bottom Segment	Mg.
25	Dibasic calcium phosphate anhydrous	51.13
	Amlodipine besylate	7.15
	Sodium starch glycolate (Explotab®)	2.48
	Magnesium stearate	0.93
	FD&C Blue #1 Aluminum Lake	<u>0.31</u>
30	Total	62.00

Manufacturing Instructions

- 35
1. Weigh each ingredient.
 2. Screen each ingredient.
 3. Triturate the color with the major diluent in

geometric proportions using a suitable mixer.

4. Add the remaining ingredients, except the lubricant, to the color mixer from step #3 and mix for desired time.

5 5. Add the lubricant to the blend from Step #4 and mix for desired time.

6. Add the blend to a suitable press fitted with the desired tooling and compress into tablets.

10

Top Segment

Mg.

Nu-Tab® (Compressible sugar 30/35 N.F.) 194.00

15

Manufacturing Instructions

1. Weigh each ingredient.

20

2. Screen each ingredient.

3. Triturate the color with the major diluent in geometric proportions using a suitable mixer.

4. Add the remaining ingredients, except the lubricant, to the color mixer from step #3 and mix for desired time.

25

5. Add the lubricant to the blend from Step #4 and mix for desired time.

6. Add the blend to a suitable press fitted with the desired tooling and compress into tablets.

30

Tabletting Instructions

1. Place the powder for amlodipine unitary segments(layer #1) in hopper #1.

2. Place the powder for first segment in hopper #2.
3. Place the powder for active layer in hopper #3.
4. Compress unitary segments to desired weight (tablets for layer #1 should form a soft compact)
- 5 5. Compress layer #1 & Layer #2 tablets to desired combined weight of layer #1 and layer #2 weight (tablets should form a soft compact)
6. Compress the bi-layer tablet to the desired total tablet weight (layer #1 weight + layer #2 weight
- 10 Tablet should be at desired hardness.

CLAIMS

- 5 1. A pharmaceutical tablet comprising a first segment one face of which is contiguous with a plurality of compositionally substantially identical unitary segments that contain a drug or drugs.
- 10 2. A pharmaceutical tablet as defined in claim 1 including two or more compositionally identical unitary segments comprising a first unitary segment and a second unitary segment, said first unitary segment and said second unitary segment each containing a drug or drugs, said first
15 unitary segment and said second unitary segment being derived from the same divided layer or layers; said first segment optionally having a score on its surface positioned between said first and said second unitary segments; said tablet optionally having additional unitary segments.
- 20
3. A pharmaceutical tablet as defined in claim 1 in which one or more additional unitary segments in addition to said first and second unitary segments are optionally present
25 and are derived from the same layer or layers as said first unitary segment.
4. A pharmaceutical tablet as defined in claim 1 in which said first unitary segment and said second unitary segment
30 contain a drug or drugs, where said first segment contains either an undetectable amount of a drug, a pharmacologically ineffective amount of drug, or a pharmacologically effective quantity of said drug or drugs present in said second segment, but has fewer milligrams of

said drug or drugs relative to the excipients in each segment than does said second segment.

5 5. A pharmaceutical tablet as defined in claim 4 in which said first unitary segment and said second unitary segment each contain a pharmacologically effective dose of said drug or drugs.

10 6. A pharmaceutical tablet as defined in claim 4 in which the first segment has from an undetectable amount of drug up to 80% of the concentration of the drug or drugs in said first unitary segment or said second unitary segment.

15 7. A pharmaceutical tablet as defined in claim 4 in which the first segment contains no more than 10 parts per million of the concentration of the drug or drugs present in said first unitary segment and said second unitary segment.

20 8. A pharmaceutical tablet as defined in claim 4 in which the first segment contains no more than 10% of the concentration of drug or drugs present in the first unitary segment and said second unitary segment.

25 9. A pharmaceutical tablet as defined in claim 1 in which the first segment contains no more than 2% the concentration of drug present in the first unitary segment and said second unitary segment.

30 10. A pharmaceutical tablet as defined in claim 1 in which said first segment is derived from a granulation that does not contain a drug.

11. A pharmaceutical tablet as defined in claim 1 in which additional unitary segments are contained in said tablet which are compositionally different from the composition of said first unitary segment and said second unitary segment
5 and are derived from a granulation containing a drug.

12. A pharmaceutical tablet as defined in claim 1 in which said first unitary and said second unitary segments are outer segments.

10

13. A pharmaceutical tablet as defined in claim 1 in which said first unitary segment and said second unitary segment adjoins other unitary segments that are outer segments.

14. A pharmaceutical tablet as defined in claim 12 in which there are interposed unitary segments between said first unitary segment and said first segment.

15. A pharmaceutical tablet as defined in claim 1 in which there is a substantially vertical score in said first segment, said score being vertically aligned with the center of the space between said first unitary segment and said second unitary segment.

25

16. A pharmaceutical tablet as defined in claim 1 in which in addition to said first unitary segment and said second unitary segment, there are two additional unitary segments which are compositionally identical.

30

17. A pharmaceutical tablet as defined in claim 1 in which said drug or drugs is or are pharmacologically effective in the treatment of cardiovascular conditions, psychiatric

conditions, diabete , thyroid disorders, pain or thrombotic disorders.

18. A pharmaceutical tablet as defined in claim 17 in
5 which said drug is warfarin.

19. A pharmaceutical tablet as defined in claim 17 in
which said drug is digoxin.

10 20. A pharmaceutical tablet as defined in claim 17 in
which said drug is levothyroxine.

21. A pharmaceutical tablet as defined in claim 1 in which
said first segment adjoins a plurality of unitary segments
15 on the side of said first segment that is opposite the
surface adjoining said first and second unitary segments.

20 22. A pharmaceutical tablet as defined in claim 1 in which
a second segment which contains a drug adjoins said first
segment on the side opposite the side where said first and
said second unitary segments are located.

25

23. A method of breaking a pharmaceutical tablet as
defined in claim 1 wherein said tablet is broken by
applying force to said first and said second unitary
segments to cause the tablet to break substantially through
30 said first segment and substantially not through any
unitary segment.

24. A method of breaking a tablet as in claim 22 that

comprises first breaking said tablet through said first segment to obtain a tablette that contains part of said first segment plus unitary segments and thereafter breaking said tablet between said first and said second unitary
5 segments so that the tablet breaks substantially completely within said first segment.

25. A method of administering a partial dose of a drug contained in a pharmaceutical tablet, said method
10 comprising breaking a pharmaceutical tablet as defined in claim 1 by breaking said tablet substantially only through said first segment to form two or more tablettes each containing a unitary segment and having a patient, other person, or other animal in need thereof ingest a tablette
15 containing a unitary segment.

26. A method of administering a partial dose of a drug contained in a pharmaceutical tablet, said method comprising breaking a pharmaceutical tablet according to
20 the method of claim 24 and having a patient, other person, or other animal in need thereof ingest a tablette formed by said breaking.

27. A compressed pharmaceutical tablet having a first
25 segment that contains a drug and that is scored from 95-99.5% of the distance between said segment and an adjoining second segment.

28. A compressed pharmaceutical tablet having a scored
30 first segment that adjoins a second segment, in which less than 5% of the quantity of drug contained in said first segment is present between said score and said second segment.

29. A compressed pharmaceutical tablet which comprises the tablet of claim 27 as a core structure in a tablet with an additional segment.
- 5
30. A compressed pharmaceutical tablet which comprises the tablet of claim 27 as a core structure in a tablet with two or more additional segments.
- 10
31. A method of breaking a pharmaceutical tablet as defined in claim 27 wherein said tablet is broken by applying force to cause the tablet to break substantially through said first segment but not through a unitary segment.
- 15
32. A method of administering a precise partial dose of a drug contained in a pharmaceutical tablet, said method comprising breaking a pharmaceutical tablet according to claim 27 by breaking said tablet through said first segment
- 20
- to form two or more tablettes and administering at least one of said tablettes to a patient, other person, or other animal in need thereof who ingests said tablette.
33. A pharmaceutical tablet as defined in claim 1 in which
- 25
- said drug or drugs is or are pharmacologically effective in the treatment of cardiovascular conditions, psychiatric conditions, diabetes, thyroid disorders, pain or thrombotic disorders.




Fig. 1




Fig. 2a

Fig. 2b






Fig. 3

**Fig. 4a****Fig. 4b**




Fig. 5




Fig. 6a




Fig. 6b




Fig. 7a

Fig. 7b

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/18631

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 9/44

US CL : 424/467

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/467

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4,824,677 (Shah et al.) 25 Apr. 1989, Figures 1-11 and claims 1-28	1-3, 5-12, 15, 21-26, 33

Y		4, 13-14, 20-21
X	US 2003/0215563 A1 (BUNICK) 20 November 2003 whole document	1-3, 5-12, 15, 21-26, 33

Y		4, 4, 13-14, 20-21
X	US 4,473,192 (Urban et al.) 25 September 1984 whole document	23-26
Y	US 3,450,252 (Hallerback) 17 June 1969 whole document	4, 13-14
Y	US 5,041,430 (Addicks et al.) 20 August 1991 (Example 3)	17, 18
Y	US 3,696,091 (Eberlein et al.) 03 October 1972 (examples 2b, 3b, 4b, 5b, 6b)	17, 19
Y	US 6,555,581 B1 (Franz et al.) 29 April 2003 (abstract)	17, 20

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

03 August 2005 (03.08.2005)

Date of mailing of the international search report

03 OCT 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Eric Silverman, PhD

Telephone No. 571-272-1600

Janice Ford
for

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/18631

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-26 and 33

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US05/18631

BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-26, and 33 drawn to a segmented tablet and method of using said tablet.

Group II, claim(s) 27-32, drawn to a segmented tablet with scoring and a method of using same..

Group I, claims 1-26 and 33 is drawn to a segmented tablet and method of using the same.

Goup II, claims 27-32 is drawn to a scored segmented tablet and methods of using the same.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of Group II is that the segmented tablet has scoring. Scoring is not required for Group I, so this special technical feature cannot be said to be shared between the two groups.